Tommaso De Pas

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. doi request reprint Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials
    Tommaso De Pas
    Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Milan, Italy
    Crit Rev Oncol Hematol 83:432-43. 2012
  2. ncbi request reprint Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study
    Gianpiero Catalano
    Division of Radiotherapy, European Institute of Oncology, Milan, Italy
    Strahlenther Onkol 181:363-71. 2005
  3. doi request reprint A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer
    Tommaso De Pas
    New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Acta Oncol 49:480-4. 2010
  4. ncbi request reprint Three-times daily radiotherapy after chemotherapy in stage III non-small cell lung cancer. Single-institution prospective study
    Gianpiero Catalano
    Division of Radiotherapy, European Institute of Oncology, Milan, Italy
    Anticancer Res 28:4121-7. 2008
  5. doi request reprint Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations
    Tommaso De Pas
    Medical Oncology Unit of Respiratory Tract and Sarcomas, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1895-901. 2011
  6. doi request reprint Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II
    Francesca Toffalorio
    Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drug Development Division, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 7:1124-30. 2012
  7. ncbi request reprint Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 2:131-4. 2007
  8. ncbi request reprint Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer
    Lorenzo Spaggiari
    Department of Thoracic Surgery European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 79:234-40. 2005
  9. doi request reprint A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases"
    Monica Casiraghi
    Thoracic Surgery Division, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1373-8. 2011
  10. ncbi request reprint Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung
    Giulia Veronesi
    Thoracic Surgery Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 48:233-40. 2005

Collaborators

Detail Information

Publications37

  1. doi request reprint Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials
    Tommaso De Pas
    Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Milan, Italy
    Crit Rev Oncol Hematol 83:432-43. 2012
    ..We will review the key points for effective active immunotherapies and combination therapies, giving an update on the most promising vaccines developed in NSCLC...
  2. ncbi request reprint Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study
    Gianpiero Catalano
    Division of Radiotherapy, European Institute of Oncology, Milan, Italy
    Strahlenther Onkol 181:363-71. 2005
    ..To evaluate the feasibility and toxicity of three-times-daily radiotherapy (3tdRT), preceded by induction chemotherapy (iCT), in stage IIIA-IIIB non-small cell lung cancer (NSCLC)...
  3. doi request reprint A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer
    Tommaso De Pas
    New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Acta Oncol 49:480-4. 2010
    ..However, these two tumor subgroups should be considered as different entities. While the efficacy of adjuvant chemotherapy has been established in patients with T1-2N1 NSCLC, its benefit in patients with T3N0 tumor remains questionable...
  4. ncbi request reprint Three-times daily radiotherapy after chemotherapy in stage III non-small cell lung cancer. Single-institution prospective study
    Gianpiero Catalano
    Division of Radiotherapy, European Institute of Oncology, Milan, Italy
    Anticancer Res 28:4121-7. 2008
    ..A prospective study for stage IIIA-B nonsmall cell lung cancer (NSCLC), with three-times daily (3td) radiotherapy (RT), after induction chemotherapy (iCT), with or without surgery...
  5. doi request reprint Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations
    Tommaso De Pas
    Medical Oncology Unit of Respiratory Tract and Sarcomas, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1895-901. 2011
    ..In this study, we report the results of treating patients with advanced non-small cell lung cancer harboring rare EGFR mutations treated with EGFR-TKIs...
  6. doi request reprint Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II
    Francesca Toffalorio
    Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drug Development Division, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 7:1124-30. 2012
    ....
  7. ncbi request reprint Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 2:131-4. 2007
    ....
  8. ncbi request reprint Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer
    Lorenzo Spaggiari
    Department of Thoracic Surgery European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 79:234-40. 2005
    ..The present study analyzed a single center's experience with this extended surgery, highlighting the surgery's technical aspects, postoperative outcomes, and oncologic results...
  9. doi request reprint A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases"
    Monica Casiraghi
    Thoracic Surgery Division, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1373-8. 2011
    ..The aim of our study was to confirm the validity of the International Registry of Lung Metastases classification system in patients who underwent curative lung metastasectomy in a single center...
  10. ncbi request reprint Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung
    Giulia Veronesi
    Thoracic Surgery Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 48:233-40. 2005
    ..In SCC patients, the magnitude of the hazard ratio was confirmed even if the precision of the estimate is decreased (p=0.06). In conclusion, T-CEA expression appears to be an important prognostic factor in early stage SSC of the lung...
  11. doi request reprint Molecular features and clinical outcome of lung malignancies in very young people
    Chiara Catania
    Division of Thoracic Oncology, European Institute of Oncology IEO, Milan, Italy
    Future Oncol 11:1211-21. 2015
    ..We describe the clinical features, outcome and incidence of druggable targets of lung cancers in patients ≤ 40 years old...
  12. doi request reprint Breast phyllodes tumor: a review of literature and a single center retrospective series analysis
    Gianluca Spitaleri
    Department of Medicine, European Institute of Oncology, Milan, Italy Electronic address
    Crit Rev Oncol Hematol 88:427-36. 2013
    ..We carried out an overview of the literature to investigate the clinical outcome of patients with phyllodes tumor. A retrospective analysis of mono-institutional series has been included as well...
  13. ncbi request reprint Prognostic role of lymph node involvement in lung metastasectomy
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 133:967-72. 2007
    ..We assessed the prognostic value of lymph node status in lung metastasectomy and the prevalence of unexpected mediastinal lymph node involvement after lymph node sampling or dissection...
  14. ncbi request reprint Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 18:949-54. 2007
    ..The study was discontinued before target accrual was reached owing to lack of efficacy of the drug. Our results do not support the efficacy of gefitinib in combination with endocrine treatment for hormone-refractory prostate cancer...
  15. pmc Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations
    Emilio Bertani
    Division of General and Laparoscopic Surgery, European Institute of Oncology, Milan, Italy
    World J Surg Oncol 10:184. 2012
    ..Surgery is still the standard treatment for aggressive fibromatosis (AF); however, local control remains a significant problem and the impact of R0 surgery on cumulative recurrence (CR) is objective of contradictory reports...
  16. doi request reprint Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice
    Chiara Catania
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Oncology 74:177-87. 2008
    ..Patients invited to take part in a clinical trial may evoke an archetype on which they may base their decision of adherence to participation, instead of on the study itself...
  17. doi request reprint Imaging of lung hamartomas by multidetector computed tomography and positron emission tomography
    Concetta De Cicco
    Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 86:1769-72. 2008
    ..Most are discovered on routine x-ray film and require further evaluation. Computed tomography (CT) is insufficient for a benign versus malignant diagnosis in about 30% of cases...
  18. ncbi request reprint Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study
    Tommaso De Pas
    Department of Medical Oncology, Division of Thoracic Surgery and Radiotherapy, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy
    Bull Cancer 91:E273-7. 2004
    ..When given as induction chemotherapy, a three-week schedule of CDDP plus GCB combination appeared to be effective, with lower toxicity and better compliance than a four-week schedule...
  19. ncbi request reprint Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare
    Tommaso De Pas
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 22:4966-70. 2004
    ....
  20. ncbi request reprint Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer
    Chiara Catania
    Division of Medical Oncology, Day Hospital Unit and Unit of Psycho oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 92:265-72. 2005
    ..The questionnaire was shown to be robust, reliable and reproducible instrument in assessing patients' prejudices towards oral anticancer treatments...
  21. doi request reprint "Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer
    Chiara Catania
    Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy
    J Cancer Educ 26:388-94. 2011
    ....
  22. doi request reprint Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires-an Italian exploratory study
    Chiara Catania
    Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    J Cancer Res Clin Oncol 142:633-48. 2016
    ..We also assessed women after the diagnosis of breast cancers, but free of disease, to help determine risks in their families...
  23. doi request reprint Sarcoma of the breast: outcome and reconstructive options
    Antonio Toesca
    Division of Senology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 12:438-44. 2012
    ..The role of adjuvant chemotherapy and radiation therapy has not been clearly defined. The aim of this single-center retrospective study was to analyze prognostic factors, outcome, and recent advances...
  24. doi request reprint Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors
    Francesca Toffalorio
    Medical Oncology Department, Thoracic Oncology Division, and Pathology and Laboratory Medicine Department, Pathology Division, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 10:392-6. 2015
    ..Indeed, previous reports did not discriminate between chromosome 7 high polysomy and EGFR amplification and/or did not investigate the concurrent presence of EGFR and KRas mutations...
  25. doi request reprint Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents
    Cristina Noberasco
    Clinical Pharmacology and New Drugs Development Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Oncology 77:358-65. 2009
    ..alpha-Interferon, thalidomide and celecoxib inhibit tumour angiogenesis by differing mechanisms...
  26. doi request reprint Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura
    Tommaso De Pas
    New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 3:938-41. 2008
    ..Treatment with imatinib should be considered for patients with recurrent or unresectable MSFTs with PDGFR expression...
  27. ncbi request reprint Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    Support Cancer Ther 3:98-102. 2006
    ..Clinicians should be aware of this increased risk, and alternative cytotoxic treatments not requiring continuous infusions should be considered for these patients...
  28. ncbi request reprint Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases
    Tommaso De Pas
    New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Crit Rev Oncol Hematol 65:1-7. 2008
    ..Both the analytic revision of the literature and our data suggest that localized DCS may be effectively treated by radical surgery and do not support the use of adjuvant treatments after radical excision...
  29. ncbi request reprint Analysis of mandibular dose distribution in radiotherapy for oropharyngeal cancer: dosimetric and clinical results in 18 patients
    Barbara A Jereczek-Fossa
    Division of Radiation Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Radiother Oncol 66:49-56. 2003
    ..The aim of our study was to analyze the mandibular dose distribution in the patients administered curative radiotherapy for squamous cell carcinoma of the oropharynx. Moreover, the clinical results have been analyzed...
  30. pmc Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets
    Francesca Toffalorio
    European Institute of Oncology, Milan, Italy
    Oncologist 19:344-5. 2014
    ..Molecular alterations of the PI3K and Ras pathways often occur in human cancer. In this trial, the pharmacokinetics, toxicity, and activity of two drugs inhibiting these pathways-everolimus and sorafenib-were investigated...
  31. ncbi request reprint Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Eur J Cancer 44:494-500. 2008
    ....
  32. ncbi request reprint Video-assisted management of malignant pleural effusion in breast carcinoma
    Roberto Gasparri
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Cancer 106:271-6. 2006
    ..The results of video-thoracoscopic approach (VATS) chemical pleurodesis was analyzed in patients with recurrent pleural effusion from breast carcinoma...
  33. ncbi request reprint Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunk
    Gianluca Lazzaro
    Melonoma Unit, European Institute of Oncology, University of Milan, Via Ripamonti 435, 20141 Milan, Italy
    Ann Surg Oncol 12:935-42. 2005
    ....
  34. ncbi request reprint Primary and recurrent retroperitoneal soft tissue sarcoma: prognostic factors affecting survival
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, University of Milano, Milan, Italy
    J Surg Oncol 93:456-63. 2006
    ..To analyze treatment and survival in 34 patients (28 resected) with primary or recurrent retroperitoneal sarcoma (RPS)...
  35. ncbi request reprint Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre
    Chiara Catania
    Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy
    Breast Cancer Res Treat 106:97-103. 2007
    ..The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy...
  36. ncbi request reprint Endometrial malignant melanoma rediagnosed as clear-cell "sugar" tumour
    Carlos Miró
    Department of Radiation Oncology, European Institute of Oncology, University of Milan, Milan, Italy
    Lancet Oncol 3:764-5. 2002
  37. ncbi request reprint Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer
    Roberto Orecchia
    Division of Radiotherapy, European Institute of Oncology, Milan, Italy
    Oncology 63:115-23. 2002
    ..We undertook a prospective phase II study to assess the feasibility and activity of a new induction chemotherapy regimen followed by hyperfractionated irradiation in locally advanced squamous cell head and neck cancer...